Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients

Carmine Zoccali, Francesca Mallamaci, Renke Maas, Francesco A. Benedetto, Giovanni Tripepi, Lorenzo S. Malatino, Alessandro Cataliotti, Ignazio Bellanuova, Rainer Böger

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Background. The endogenous inhibitor of nitric oxide (NO), asymmetric dimethylarginine (ADMA), is a strong predictor of adverse cardiovascular outcomes in patients with end-stage renal disease (ESRD). Methods. Since arterial and cardiac remodeling is associated with altered endothelial microcirculatory responses to forearm ischemia (a NO-dependent response), interference of ADMA with the NO system may be important for the pathogenesis of left ventricular hypertrophy (LVH) in these patients. This study sought to identify the relationship between plasma ADMA and LV geometry and function in a cohort of 198 hemodialysis patients. Results. Plasma ADMA was significantly higher (P = 0.008) in patients with LVH (median 3.00 μmol/L, inter-quartile range 1.73 to 3.97 μmol/L) than in those without this alteration (1.88 μmol/L, 1.15 to 3.56 μmol/L) and was significantly related to left ventricular (LV) mass (r = 0.26, P < 0.001). Interestingly, ADMA was much higher (P < 0.001) in patients with concentric LVH (3.60 μmol/L, 2.90 to 4.33 μmol/L) than in patients with eccentric LVH (2.17 μmol/L, 1.47 to 3.24 μmol/L) or normal LV mass (1.76 μmol/L, 1.13 to 2.65 μmol/L). Furthermore, plasma ADMA was higher (P = 0.02) in patients with systolic dysfunction (3.52 μmol/L, 2.08 to 5.87 μmol/L) than in those with normal LV function (2.58 μmol/L, 1.53 to 3.84 μmol/L) and inversely related to ejection fraction (EF; r = -0.25, P < 0.001). The link between ADMA and LV mass and EF was confirmed by multivariate analysis (ADMA vs. LVMI, β = 0.17, P = 0.006; ADMA vs. EF, β = -0.24, P < 0.001). Conclusions. Overall, this study indicates that raised plasma concentration of ADMA is associated to concentric LVH and LV dysfunction. Intervention studies are needed to see whether the link between ADMA and concentric LVH remodeling and LV dysfunction is a causal one.

Original languageEnglish (US)
Pages (from-to)339-345
Number of pages7
JournalKidney International
Volume62
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Ventricular Remodeling
Left Ventricular Hypertrophy
Renal Dialysis
Nitric Oxide
Left Ventricular Dysfunction
Left Ventricular Function
N,N-dimethylarginine
Forearm
Chronic Kidney Failure
Multivariate Analysis
Ischemia

Keywords

  • ADMA
  • Cardiovascular
  • Dialysis
  • LVH
  • Nitric oxide
  • Risk
  • Systolic dysfunction
  • Uremia

ASJC Scopus subject areas

  • Nephrology

Cite this

Zoccali, C., Mallamaci, F., Maas, R., Benedetto, F. A., Tripepi, G., Malatino, L. S., ... Böger, R. (2002). Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney International, 62(1), 339-345. https://doi.org/10.1046/j.1523-1755.2002.00437.x

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. / Zoccali, Carmine; Mallamaci, Francesca; Maas, Renke; Benedetto, Francesco A.; Tripepi, Giovanni; Malatino, Lorenzo S.; Cataliotti, Alessandro; Bellanuova, Ignazio; Böger, Rainer.

In: Kidney International, Vol. 62, No. 1, 2002, p. 339-345.

Research output: Contribution to journalArticle

Zoccali, C, Mallamaci, F, Maas, R, Benedetto, FA, Tripepi, G, Malatino, LS, Cataliotti, A, Bellanuova, I & Böger, R 2002, 'Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients', Kidney International, vol. 62, no. 1, pp. 339-345. https://doi.org/10.1046/j.1523-1755.2002.00437.x
Zoccali, Carmine ; Mallamaci, Francesca ; Maas, Renke ; Benedetto, Francesco A. ; Tripepi, Giovanni ; Malatino, Lorenzo S. ; Cataliotti, Alessandro ; Bellanuova, Ignazio ; Böger, Rainer. / Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. In: Kidney International. 2002 ; Vol. 62, No. 1. pp. 339-345.
@article{c5786fe1718c45999f8446eced242c95,
title = "Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients",
abstract = "Background. The endogenous inhibitor of nitric oxide (NO), asymmetric dimethylarginine (ADMA), is a strong predictor of adverse cardiovascular outcomes in patients with end-stage renal disease (ESRD). Methods. Since arterial and cardiac remodeling is associated with altered endothelial microcirculatory responses to forearm ischemia (a NO-dependent response), interference of ADMA with the NO system may be important for the pathogenesis of left ventricular hypertrophy (LVH) in these patients. This study sought to identify the relationship between plasma ADMA and LV geometry and function in a cohort of 198 hemodialysis patients. Results. Plasma ADMA was significantly higher (P = 0.008) in patients with LVH (median 3.00 μmol/L, inter-quartile range 1.73 to 3.97 μmol/L) than in those without this alteration (1.88 μmol/L, 1.15 to 3.56 μmol/L) and was significantly related to left ventricular (LV) mass (r = 0.26, P < 0.001). Interestingly, ADMA was much higher (P < 0.001) in patients with concentric LVH (3.60 μmol/L, 2.90 to 4.33 μmol/L) than in patients with eccentric LVH (2.17 μmol/L, 1.47 to 3.24 μmol/L) or normal LV mass (1.76 μmol/L, 1.13 to 2.65 μmol/L). Furthermore, plasma ADMA was higher (P = 0.02) in patients with systolic dysfunction (3.52 μmol/L, 2.08 to 5.87 μmol/L) than in those with normal LV function (2.58 μmol/L, 1.53 to 3.84 μmol/L) and inversely related to ejection fraction (EF; r = -0.25, P < 0.001). The link between ADMA and LV mass and EF was confirmed by multivariate analysis (ADMA vs. LVMI, β = 0.17, P = 0.006; ADMA vs. EF, β = -0.24, P < 0.001). Conclusions. Overall, this study indicates that raised plasma concentration of ADMA is associated to concentric LVH and LV dysfunction. Intervention studies are needed to see whether the link between ADMA and concentric LVH remodeling and LV dysfunction is a causal one.",
keywords = "ADMA, Cardiovascular, Dialysis, LVH, Nitric oxide, Risk, Systolic dysfunction, Uremia",
author = "Carmine Zoccali and Francesca Mallamaci and Renke Maas and Benedetto, {Francesco A.} and Giovanni Tripepi and Malatino, {Lorenzo S.} and Alessandro Cataliotti and Ignazio Bellanuova and Rainer B{\"o}ger",
year = "2002",
doi = "10.1046/j.1523-1755.2002.00437.x",
language = "English (US)",
volume = "62",
pages = "339--345",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients

AU - Zoccali, Carmine

AU - Mallamaci, Francesca

AU - Maas, Renke

AU - Benedetto, Francesco A.

AU - Tripepi, Giovanni

AU - Malatino, Lorenzo S.

AU - Cataliotti, Alessandro

AU - Bellanuova, Ignazio

AU - Böger, Rainer

PY - 2002

Y1 - 2002

N2 - Background. The endogenous inhibitor of nitric oxide (NO), asymmetric dimethylarginine (ADMA), is a strong predictor of adverse cardiovascular outcomes in patients with end-stage renal disease (ESRD). Methods. Since arterial and cardiac remodeling is associated with altered endothelial microcirculatory responses to forearm ischemia (a NO-dependent response), interference of ADMA with the NO system may be important for the pathogenesis of left ventricular hypertrophy (LVH) in these patients. This study sought to identify the relationship between plasma ADMA and LV geometry and function in a cohort of 198 hemodialysis patients. Results. Plasma ADMA was significantly higher (P = 0.008) in patients with LVH (median 3.00 μmol/L, inter-quartile range 1.73 to 3.97 μmol/L) than in those without this alteration (1.88 μmol/L, 1.15 to 3.56 μmol/L) and was significantly related to left ventricular (LV) mass (r = 0.26, P < 0.001). Interestingly, ADMA was much higher (P < 0.001) in patients with concentric LVH (3.60 μmol/L, 2.90 to 4.33 μmol/L) than in patients with eccentric LVH (2.17 μmol/L, 1.47 to 3.24 μmol/L) or normal LV mass (1.76 μmol/L, 1.13 to 2.65 μmol/L). Furthermore, plasma ADMA was higher (P = 0.02) in patients with systolic dysfunction (3.52 μmol/L, 2.08 to 5.87 μmol/L) than in those with normal LV function (2.58 μmol/L, 1.53 to 3.84 μmol/L) and inversely related to ejection fraction (EF; r = -0.25, P < 0.001). The link between ADMA and LV mass and EF was confirmed by multivariate analysis (ADMA vs. LVMI, β = 0.17, P = 0.006; ADMA vs. EF, β = -0.24, P < 0.001). Conclusions. Overall, this study indicates that raised plasma concentration of ADMA is associated to concentric LVH and LV dysfunction. Intervention studies are needed to see whether the link between ADMA and concentric LVH remodeling and LV dysfunction is a causal one.

AB - Background. The endogenous inhibitor of nitric oxide (NO), asymmetric dimethylarginine (ADMA), is a strong predictor of adverse cardiovascular outcomes in patients with end-stage renal disease (ESRD). Methods. Since arterial and cardiac remodeling is associated with altered endothelial microcirculatory responses to forearm ischemia (a NO-dependent response), interference of ADMA with the NO system may be important for the pathogenesis of left ventricular hypertrophy (LVH) in these patients. This study sought to identify the relationship between plasma ADMA and LV geometry and function in a cohort of 198 hemodialysis patients. Results. Plasma ADMA was significantly higher (P = 0.008) in patients with LVH (median 3.00 μmol/L, inter-quartile range 1.73 to 3.97 μmol/L) than in those without this alteration (1.88 μmol/L, 1.15 to 3.56 μmol/L) and was significantly related to left ventricular (LV) mass (r = 0.26, P < 0.001). Interestingly, ADMA was much higher (P < 0.001) in patients with concentric LVH (3.60 μmol/L, 2.90 to 4.33 μmol/L) than in patients with eccentric LVH (2.17 μmol/L, 1.47 to 3.24 μmol/L) or normal LV mass (1.76 μmol/L, 1.13 to 2.65 μmol/L). Furthermore, plasma ADMA was higher (P = 0.02) in patients with systolic dysfunction (3.52 μmol/L, 2.08 to 5.87 μmol/L) than in those with normal LV function (2.58 μmol/L, 1.53 to 3.84 μmol/L) and inversely related to ejection fraction (EF; r = -0.25, P < 0.001). The link between ADMA and LV mass and EF was confirmed by multivariate analysis (ADMA vs. LVMI, β = 0.17, P = 0.006; ADMA vs. EF, β = -0.24, P < 0.001). Conclusions. Overall, this study indicates that raised plasma concentration of ADMA is associated to concentric LVH and LV dysfunction. Intervention studies are needed to see whether the link between ADMA and concentric LVH remodeling and LV dysfunction is a causal one.

KW - ADMA

KW - Cardiovascular

KW - Dialysis

KW - LVH

KW - Nitric oxide

KW - Risk

KW - Systolic dysfunction

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0036315607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036315607&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2002.00437.x

DO - 10.1046/j.1523-1755.2002.00437.x

M3 - Article

VL - 62

SP - 339

EP - 345

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -